Common questions about Denagard 12.5% (FAQ)
Q: What specific conditions is Denagard 12.5% licensed to treat?
Official regulatory documents indicate the medicine is authorized for conditions including swine dysentery associated with Brachyspira hyodysenteriae and swine pneumonia due to Actinobacillus pleuropneumoniae in pigs, and certain Mycoplasma infections in poultry. This reflects the specific indications found in product licensing information.
Q: Are there any long-term effects associated with using Denagard 12.5%?
Regulatory summaries of clinical research indicate that long-term outcomes are not fully established regarding the maintenance of symptom control after treatment. This is because follow-up periods in the available research were often limited to the duration of the initial treatment course.
Q: How does Denagard 12.5% compare to other drugs used for the same purpose, according to regulatory sources?
Regulatory documents classify this medicine as a Pleuromutilin antibiotic, describing its specific mechanism of action by inhibiting microbial protein synthesis. Regulatory information defines critical safety contraindications with certain other medicines, specifically polyether ionophores (like Monensin and Salinomycin), rather than providing therapeutic comparisons to other drug classes.
Q: What research themes are commonly explored in studies about Denagard 12.5%?
Studies and official summaries commonly explore themes related to observable changes, such as monitoring clinical signs like coughing or diarrhea. Researchers also examine pathogen shedding patterns, evaluate lesion scores in post-mortem analysis, and study the drug's properties through pharmacokinetic/pharmacodynamic (PK/PD) studies.
Q: Is Denagard 12.5% considered safe for use in pregnant or nursing populations?
Official documentation presents nuanced information on reproductive status. Some regulatory bodies document the medicine as useable during pregnancy and lactation in pigs. However, it is also officially noted that the effects on swine reproductive performance have not been definitively determined in all studies, indicating a known data limitation.
Q: What is the difference between Denagard 12.5% and a higher or lower concentration product?
Official documents indicate that the active ingredient, Tiamulin hydrogen fumarate, is available in various concentrations (e.g., 12.5% and 45% solutions) in different markets. These varying concentrations often correlate with different licensed indications and mandatory withdrawal periods.
Q: What is the significance of the '12.5%' concentration?
The '12.5%' refers to the concentration of the active ingredient, Tiamulin hydrogen fumarate, in the liquid product, defined as 12.5% weight per volume (w/v). This specific concentration is a factor used when calculating the necessary volume of concentrate for dilution into the drinking water supply.
Q: Can Denagard 12.5% be given to all age groups?
Official administration instructions detail use for certain groups, such as growing and finishing pigs, and regulatory studies reference its use in young birds. However, the regulatory label does not universally confirm safety or suitability for all possible age groups or classes of animals.
Q: Are there any specific food items or beverages that can affect how Denagard 12.5% works?
Regulatory documents explicitly contraindicate the use of this medicine with feeds containing polyether ionophores (a type of feed additive or drug). No other specific food or beverage interactions are documented as restrictions in the primary drug label.
Q: Is Denagard 12.5% known to cause changes in mood or behavior?
Official safety documents, especially when describing effects seen in the context of an overdose, mention observations such as an 'apparent calming effect' or lethargy (sluggishness) in pigs. These are noted changes in behavior; other generalized mood changes are not commonly listed in the safety information.
Q: Does Denagard 12.5% have a defined risk classification (e.g., pregnancy category, if applicable)?
Regulatory documents indicate that, as a veterinary product, this medicine is not assigned the human-centric FDA Pregnancy Categories (A, B, C, D, X). However, safety documentation does address reproductive safety by noting its use in pregnant and lactating pigs in some regions, while also officially acknowledging data limitations.
Q: Why is Denagard 12.5% sometimes referred to by a different brand name?
The medicine is based on the generic active ingredient Tiamulin hydrogen fumarate. Like many medicinal products, the drug is sold globally under a variety of invented brand names (e.g., Denagard, Vetmulin, Tiamutin) depending on the country or manufacturer.
Q: Does Denagard 12.5% have a defined withdrawal period before certain activities are resumed?
Official labels include Residue Warnings that define a withdrawal period, which is the required amount of time to be observed after the last treatment before treated animals can be sent to slaughter for food production. This period typically ranges from 3 to 7 days, depending on the administered dose.
Q: Are there any documented cases of overdose with Denagard 12.5%?
Regulatory information describes the effects observed in the target species following an overdose, such as transitory salivation, vomiting, and lethargy, rather than listing specific, publicly documented case reports. This information helps define the product's toxicity profile.
